NCT06623474Recruiting
Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 9 Oct 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
As one of the common malignant tumors in China, primary liver cancer, whose incidence rate and mortality rate are always in the top five, is seriously threatening the health of people. Therefore, early diagnosis and treatment of primary liver cancer are of great significance. In recent years, the incidence of primary liver cancer, which is caused by hepatic steatosis or metabolic dysfunction-related liver disease, is increasing year by year, and it has become one of the fastest rising causes in some developed countries. More and more studies have also confirmed that the levels of different kinds of lipids and their metabolites are correlated with the development of hepatocellular carcinoma. In this study, the researchers performed qualitative and quantitative analyses of various common lipid metabolites in plasma and liver cancer tissues of hepatic resection patients with hepatocellular carcinoma, collected tumor-related pathological data from the patients, and investigated the correlation between the lipid metabolites and the development of hepatocellular carcinoma, in order to provide a new idea for the early diagnosis and treatment of primary hepatocellular carcinoma, as well as for screening of hepatocellular carcinoma markers.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 900 (estimated)
- First submitted
- 30 Sept 2024
- Start date
- 1 Jul 2024
- Primary completion date
- 30 Jun 2032
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06623474
What you commit to
- Study type: Observational
- Planned participants: 900
- From 1 Jul 2024 to the primary completion date, 30 Jun 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Surgery with biliary tract exploration or reconstruction in the presence of biliary obstruction.
- Surgery combined with splenectomy or splenic artery ligation
Other illness
- Patients with hepatic malignant tumors with invasion of the main portal vein and its first-order branches, the common hepatic duct and its first-order branches, the main hepatic vein and the inferior vena cava, or extrahepatic metastases.
- Preoperative combination of cardiac, pulmonary, renal and other organs with major underlying diseases.
Other
- In the judgment of the investigator, they are not suitable to participate in this study.
Who the study is looking for
- Patients aged 18-80 years old undergoing hepatic resection for hepatocellular carcinoma (diagnostic criteria for hepatocellular carcinoma refer to the guidelines for the diagnosis and treatment of primary hepatocellular carcinoma).
- Voluntary signing of informed consent
Age in the registry: 18 years to 80 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanfang Hospital Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
Related publications
- Preoperative plasma ceramide profiling coupled with machine learning accurately predicts recurrence of hepatocellular carcinoma after resection.Lipids Health Dis · 2025 · PMID 41194075
This page is information, not medical advice. Discuss any trial with your doctor.